Feature

Readmission burden high for those with sickle cell disease


 

Patients with sickle cell disease are 2.5 times more likely to be readmitted within 30 days of a hospital stay than those without SCD, according to the Agency for Healthcare Research and Quality.

30-day readmisison rates with or without SCD by age, 2016

The 30-day all-cause readmission rate for index stays with a principal diagnosis of SCD was 33.5% in 2016, compared with 12.5% for non-SCD hospital stays. Patients with a secondary diagnosis of SCD had readmission rates of 32.9% with a pain crisis and 21.0% without one, and the overall readmission rate for an index stay with any SCD diagnosis was 31.1%, Kathryn R. Fingar, PhD, MPH, of IBM Watson Health, Sacramento, Calif., and associates wrote in an AHRQ statistical brief.

When age is factored in, the readmission gap between a principal SCD diagnosis and non-SCD becomes even greater – and smaller. The difference was greatest for patients aged 18-34 years – 39.4% with a principal diagnosis of SCD versus 7.8% without any SCD – and then narrowed as patients got older. For those aged 65 years and older, the rates were 22.6% with a principal diagnosis of SCD and 15.9% without, the investigators reported.

The approximately 100,000 Americans with SCD accounted for 134,000 admissions in 2016, and more than three-quarters of those stays involved a pain crisis. A principal diagnosis of SCD was recorded for almost 96,000 of those visits, and nearly all (96%) of those stays involved a pain crisis. For those with a secondary diagnosis of SCD, the most common reasons for hospitalization were diseases of the respiratory system (14.3% of those stays) and infectious and parasitic diseases (13.2%).

Patients with SCD were more likely than non-SCD patients to be admitted from the ED (79.6% vs. 51.3%), and they were more likely to discharged against medical advice (4.1% vs. 1.2%). Among those who left the hospital against medical advice, patients with SCD were much more likely to be readmitted than those without SCD (46.6% vs. 26.5%), based on data from the AHRQ’s Nationwide Readmissions Database.

Improved treatment of complications has “reduced mortality rates so that nearly 95% of individuals born with SCD in the United States reach 18 years of age [but] limited knowledge of SCD treatment guidelines among healthcare professionals continues to pose a barrier to effective patient-provider relationships, and this barrier contributes to lower quality of life,” Dr. Fingar and associates wrote.

Recommended Reading

Gabapentin falls short in treating sickle cell pain
MDedge Family Medicine
Oral voxelotor improves hemoglobin in sickle cell disease
MDedge Family Medicine
Orthopedic complications in sickle cell require prompt action
MDedge Family Medicine
Femoral head decompression relieves SCD hip pain
MDedge Family Medicine
Study: Why urban sickle cell patients quit hydroxyurea
MDedge Family Medicine
Crizanlizumab shows posttreatment effect in sickle cell
MDedge Family Medicine
Noninvasive prenatal test may detect sickle cell disease
MDedge Family Medicine
Sickle cell unit running 24/7 reduces readmissions, emergency visits
MDedge Family Medicine
Ongoing research aims to improve transplant outcomes in sickle cell
MDedge Family Medicine
Hypoxia-related discoveries net Nobel Prize
MDedge Family Medicine